Although Parker doesn't have NOMID or CAPS he does take Anakinra during a flare. Hopefully Anakinra will soon be approved for TRAPS and other diseases!

FDA
approves Kineret for the treatment of NOMID

Sobi (STO: SOBI) today announced that the US Food and Drug
Administration (FDA) has approved Kineret® (anakinra) for the treatment of
children and adults with neonatal-onset multisystem inflammatory disease
(NOMID). Kineret® is the first and only FDA-approved therapy for NOMID, the most
severe form of cryopyrin associated periodic syndromes (CAPS).

This is the first approval allowing the use of Kineret in
children. Kineret was approved for NOMID under an Orphan Drug designation. A
priority review was granted by the FDA based on the product's potential to
provide a significant advance in therapy for the NOMID patient population where
no adequate therapy exists. Sobi will provide a prefilled syringe with a
graduated label to allow flexible dosing in children. Kineret has been approved
for the reduction of signs and symptoms of Rheumatoid Arthritis (RA) in adults
since 2001.

CAPS is, in its most severe form of NOMID, a life-long and
severely debilitating disease. The disease is associated with an overproduction
of an immune system protein known as interleukin-1 (IL-1). Untreated patients
develop progressive hearing and vision loss, variable degrees of cognitive
impairment and joint contractures. Treatment of NOMID patients for 5 years with
Kineret demonstrated that, in addition to controlling the daily symptoms of the
disease such as fever, rash, headache and joint pain, important central nervous
system (CNS) functions such as hearing and vision remain stable and do not
progress on treatment. "In order to prevent organ damage that results from
untreated disease, we have learned that early diagnosis and the initiation of
IL-1 blocking therapy are critical," said Dr. Raphaela Goldbach-Mansky, the
principal investigator of the NOMID study that was conducted at the National
Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), part of
the National Institutes of Health (NIH) in Bethesda, MD, USA.

Dr. Geoffrey McDonough, CEO of Sobi, said "The FDA approval of
Kineret for NOMID is a significant result from a long-term collaboration with
the NIH and patient societies, and marks an important milestone in our effort to
bring therapeutics options to patients with rare inflammatory diseases. We look
forward to making Kineret more widely available to patients with NOMID in the
United States this year."

About CAPS and NOMID Cryopyrin associated periodic syndromes (CAPS) are a group
of rare inherited autoinflammatory diseases caused by autosomal dominant
mutations in a gene called NLRP3. CAPS is characterized by uncontrolled
overproduction of IL-1beta. IL-1 induces a number of inflammatory responses such
as fever, pain sensitization, bone and cartilage destruction and acute plasma
protein responses. In the most severe form NOMID, also called chronic infantile
neurologic cutaneous and arthritis syndrome (CINCA) in Europe, it is associated
with increased mortality and fever, rash, chronic aseptic meningitis,
sensorineural hearing loss, craniofacial abnormalities, and bone lesions. When
of intermediate severity, the disease is typically associated with episodic,
intense and enduring flares and morbidity, including progressive hearing loss
and kidney failure secondary to amyloidosis (a condition where amyloid proteins
are deposited in organs and/or tissues). The mildest form presents with
cold-induced episodes of fever, rash and malaise. The incidence of CAPS is
estimated to be 1:1,000,000 worldwide.

About Kineret (anakinra) Kineret is a recombinant protein drug approved for the
treatment of children and adults with NOMID, and the reduction in signs and
symptoms and slowing the progression of structural damage in moderately to
severely active rheumatoid arthritis (RA), in patients 18 years of age or older
who have failed one or more disease modifying antirheumatic drugs (DMARDs).
Kineret blocks the biological activity of IL-1 by binding to the interleukin-1
type 1 receptor, expressed in a wide variety of tissues and organs. IL-1 is a
key mediator of inflammation and driver of autoinflammatory diseases in both
adults and children. For more information on Kineret see the Prescribing
Information. (www.kineretrx.com)

Sobi is an international specialty healthcare company dedicated
to rare diseases. Our mission is to develop and deliver innovative therapies and
services to improve the lives of patients. The product portfolio is primarily
focused on inflammation and genetic diseases, with three late stage biological
development projects within hemophilia and neonatology. We also market more than
40 specialty and rare disease products for partner companies. Sobi is a pioneer
in biotechnology with world-class capabilities in protein biochemistry and
biologics manufacturing. In 2011, Sobi had total revenues of SEK 1.9 billion (€
214 M) and about 500 employees. The share (STO: SOBI) is listed on NASDAQ OMX
Stockholm. More information is available at www.sobi.com.